Skip to main content
← Mamaya research
For payers, employers & benefits leaders

The Math of Specialized Care

Generalist mental-health routing for women in transition is a hidden cost center. Here is what a specialized layer recovers — and how we prove it.

White paper · Health economics · ~10 min read

The thesis in one line

Women moving through pregnancy, pregnancy loss, the perinatal year, perimenopause, and cancer treatment carry some of the highest mental-health risk in medicine — and some of the lowest rates of effective treatment. When that care is routed to a generalist who does not specialize in her clinical picture, she tends not to stay in it. Disengagement is not a soft cost. It cascades into emergency visits, repeat workups, lost workdays, and, at the extreme, preventable death.

This paper lays out the size of that cost, why generalist routing produces it, and what changes when a specialized, measurement-based layer sits between the woman and the system. The published evidence is sobering on its own; the operating model that recovers it is straightforward.

Generalist mental-health care for specialized populations produces generalist outcomes. Generalist outcomes are expensive.

The scale

Five numbers every benefits leader should know

$14.2B

Annual U.S. societal cost of untreated perinatal mood and anxiety disorders, following each mother–child pair from pregnancy through five years postpartum.

Mathematica / March of Dimes, 2019 (2017 birth cohort)
$31,800

Average cost per mother–child pair affected by an untreated perinatal mood or anxiety disorder.

Mathematica, 2019
22.5%

Share of U.S. pregnancy-related deaths with a mental-health condition as the underlying cause — the single leading cause. 87% of all pregnancy-related deaths are preventable.

CDC Maternal Mortality Review Committees, 2021 data
~85%

Share of women with a perinatal mood or anxiety disorder who receive no treatment at all; 50–70% of cases go undetected.

Peer-reviewed literature; American Academy of Pediatrics
$26.6B

Annual U.S. cost of menopause symptoms including medical spend — $1.8B in lost work time alone.

Mayo Clinic Proceedings, 2023

These are not edge cases. Perinatal mood and anxiety disorders affect roughly one in five women — the most common complication of childbirth, and, per the American Academy of Pediatrics, the most underdiagnosed obstetric complication in America. Four in five women experience menopausal symptoms, with an average diagnostic delay measured in years. The prevalence is enormous; the treated fraction is small; and the gap between them is where the spend lives.

The mechanism

Why generalist care fails specialized populations

A woman in reproductive grief, oncology distress, or perimenopause does not present like a textbook case of depression or anxiety, and she knows it. When she is matched with a clinician who treats her loss like an ordinary breakup, or her perimenopausal anxiety as free-floating worry, the therapeutic relationship never forms. She quits — usually inside the first few sessions — and does not re-engage with care for a year or more.

What happens in that year is predictable, and every step of it shows up on a claims report.

The cost cascade
  • Early drop-out — the initial sessions are spent and wasted; she disengages feeling unseen and avoids care for 12+ months.
  • Self-soothing behaviors — alcohol use, sleep-aid misuse, and disordered eating rise with untreated life-stage distress, generating downstream medical claims.
  • Workplace absenteeism — untreated perinatal loss, oncology distress, or perimenopause drives additional missed workdays each year, a direct productivity loss.
  • Recurring claims and ED visits — undiagnosed cases accumulate repeat primary-care visits, specialist workups, and emergency visits before the right care is finally found, often 18–24 months later.

Modeled across a perimenopausal workforce, a panel of miscarriage patients, or a breast-cancer cohort, this silent fragmentation runs an estimated $7,500–$16,000 per woman, per episode.

Illustrative model — conservative industry ranges; see methodology note
The fix

What a specialized layer changes

Specialization is not a marketing posture; it is an operating model with four moving parts.

  • Life-stage matching — a woman is routed to a clinician trained in her specific picture (perinatal loss, oncology distress, perimenopause), within days, not weeks.
  • Measurement-based care — a standardized score is taken at baseline and repeated on a fixed cadence, so progress is visible and stalls are caught early.
  • Stay-in-care design — programs, coaching, therapy, and medication management sit on one tiered path, so a woman steps up or down without re-introducing herself or losing continuity.
  • Cross-care coordination — Mamaya carries the mental-health side while her medical providers keep the physical side, with structured hand-offs in both directions.

The result is the inverse of the cascade: she stays in care, her treatment adherence on the medical side holds, her missed workdays fall, and the episode closes instead of recurring.

The ROI framework

How to model Mamaya against your population

Every engagement conversation starts with your numbers. The shape of the math is the same each time.

Inputs — what we need from you
  • Population size and demographic split (reproductive-age, peri/menopausal, oncology cohort)
  • Claim rate for mental-health and co-morbid medical care in that population
  • Average claim cost, ED rate, and specialist visit rate
  • Absenteeism estimate or benchmark for the segment
  • Current mental-health vendor (EAP, insurance panel, or none)
Outputs — what the model returns
  • Baseline: projected fragmentation spend over 12 months
  • Mamaya scenario: projected direct spend plus avoided claims
  • Per-woman ROI and payback period
  • Population-level savings band (conservative to aggressive uptake)
  • Quality signals: time-to-stability, engagement rate, outcome trajectory
Proof, not promises

How we prove the outcome

Cost models are only as credible as the outcomes underneath them, so we measure outcomes the way payers expect them measured. Every woman is scored at intake on a validated instrument — PHQ-9 for depression, GAD-7 for anxiety, EPDS in the perinatal period — and re-scored on a fixed cadence through discharge. Because it is the same scale each time, we can report mean change from baseline, the share achieving clinical response (a reduction of 50% or more), and the share reaching remission.

Those results are rolled up to the population level, de-identified, and shared back to each partner as a joint annual outcomes brief. No individual is ever identifiable, and cohorts below a minimum size are suppressed. That brief is where the ROI in this paper stops being a model and becomes your data.

Methodology note: published figures are cited below. The $7,500–$16,000 per-episode cascade is an illustrative model built from conservative industry ranges (Bureau of Labor Statistics absenteeism data, MarketScan claims research, oncology-distress literature, and SHRM replacement-cost estimates). It is intended for directional modeling, not as a published claim; we build the specific model against your population in the ROI walkthrough.

Sources
  1. Mathematica & March of Dimes — Societal Costs of Untreated Perinatal Mood and Anxiety Disorders in the United States (2019).
  2. Maternal Mental Health Leadership Alliance — Key Takeaways from the Latest CDC Data on Pregnancy-Related Deaths (2021 MMRC data; mental-health conditions the leading underlying cause).
  3. Faubion S. et al. — Impact of Menopause Symptoms on Women in the Workplace. Mayo Clinic Proceedings (2023).
  4. MGH Center for Women's Mental Health — prevalence and treatment gaps in perinatal mood and anxiety disorders; American Academy of Pediatrics on underdiagnosis.

Bring this to your population.

We model the math against your numbers and walk your clinical and commercial teams through it in 30 minutes.